Better Health for All

Cellectis' core business is developing gene-edited CAR T-cell therapies for various aggressive cancers, including Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, and Triple Negative Breast Cancer.

The company has 8 products in clinical development and 3 preclinical assets. Clinical trial data for lasme-cel in relapsed/refractory B-ALL showed an Overall Response Rate of 68% (n=22), 83% at RP2D (n=12), and 100% in the target Phase 2 population (n=9), with 78% of patients proceeding to transplant. Eti-cel for r/r NHL showed an 86% ORR and 57% CR rate (n=7). However, a patient death from cardiac arrest during a UCARTCS1 trial in 2020 led to an FDA clinical hold, which was resolved by the end of 2020. For lasme-cel, adverse events included CRS in 2.5% and ICANS in 5% of patients, with 8 related serious adverse events and 1 dose-limiting toxicity. The illustrative 2025 anchor price for lasme-cel is approximately $515,000 in the U.S. and $365,000 in the EU4 and UK. The company aims to sponsor inclusive clinical trials, provides approved Informed Consent Forms, and registers trials on clinicaltrials.gov. Cellectis has been advancing its gene-editing platform for over 24 years and has a diversified intellectual property portfolio. The company has a target of -15% CO2 impact by 2030 and offers wellness programs for employees, including learning sessions on work-life balance and stress management. Cellectis also prioritizes cybersecurity, following NIST guidance and requiring annual employee training.

Fair Money & Economic Opportunity

Cellectis S.A. is a gene editing company focused on developing CAR-T cell therapies.

The provided articles confirm that the company's operations are entirely within the biotechnology sector and do not involve lending, deposit services, or any other financial products or services for consumers. Therefore, all KPIs related to the 'Fair Money & Economic Opportunity' value are not applicable to Cellectis S.A.

Fair Pay & Worker Respect

Cellectis reports that 0% of its employees are covered by collective bargaining agreements.

The company's 2023 Colleague Voix Survey indicates that 82% of colleagues consider it a great place to work, with 93% believing they are treated fairly regardless of race or ethnicity, and 90% feeling empowered to make decisions. However, a Glassdoor employee rating shows a lower engagement score of 2.9 out of 5 stars. In the past three years, there have been two minor labor-law infractions related to a French Tax Authority audit, resulting in court orders to reimburse $0.7 million for 2017-2018 research tax credits and $0.6 million for 2015-2016 credits.

Honest & Fair Business

No specific, concrete data points or quantitative evidence relevant to any of the 'Honest & Fair Business' KPIs were found in the provided articles.

All articles explicitly state a lack of relevant data for these metrics, or provide information that does not directly quantify the KPI.

Kind to Animals

Cellectis S.A. conducts pre-clinical animal studies, which are explicitly stated as required by the FDA.

The company is listed as engaging in 'Animal Testing' as an animal usage activity. While no specific volume is provided, the company mentions conducting 'limited testing in animals'.

No War, No Weapons

Cellectis S.A. is a gene-editing company focused on developing CAR-T cell therapies for cancer. The company's 2023 ESG Report explicitly states that its activities do not directly involve arms contracts, dual-use technology with military applications, or sales to embargoed regimes.

Therefore, all KPIs related to military or conflict-related activities are deemed 'Not Applicable' to its core operations. This includes revenue from arms contracts, R&D in dual-use technologies, sales to sanctioned regimes, investment in peacebuilding, conflict divestment policies, board oversight of defense, export certifications, lobbying against arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines for weapons, exposure to controversial weapons, war risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, and ethical red lines compliance.

Planet-Friendly Business

No data relevant to the Planet-Friendly Business metrics could be extracted from the provided article.

The article indicates that the URL leads to financial reports, not general sustainability or business strategy information, and does not contain the substance of those reports.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities'. The 2024 financial report explicitly lists all relevant KPIs as null.

The 2023 ESG report summary states that it does not provide specific data on community engagement, cultural impact assessments, or reinvestment in local communities, and explicitly lists the absence of data for all relevant KPIs. The careers page also confirms a lack of quantitative data for these metrics.

Safe & Smart Tech

Cellectis reported no material cybersecurity breaches in 2023 and, to the company's knowledge, no breaches requiring material cost or liability or duty to notify up to February 2023.

The company has strengthened monitoring tools and response procedures, and applies a risk-based approach to cybersecurity governance. Employees are required to complete a mandatory security training course each year, and the IT Security team conducts continuous simulated phishing campaigns and shares regular awareness communications. The company has modernized customer and employee multi-factor authentication systems. Cellectis states it is in material compliance with all applicable data privacy and security laws, including GDPR, and has not received notice of any actual or potential violations from governmental authorities. The company provides users with the right to access, rectify, erase, or restrict processing of their personal data, and the right to data portability and to withdraw consent. Data transfers to the US are protected by appropriate safeguards, such as standard data protection clauses.